SITC's Cancer Immunotherapy Guidelines program is a collection of clinical practice guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure recommendations are unbiased, transparent, and balanced.
The lymphoma guideline provides a valuable clinical decision-making tool to help guide oncologists and other advanced practice providers on topics including biomarkers, the selection of appropriate immunotherapeutic regimens, treatment response and monitoring, toxicity management, and patient quality of life considerations.
"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma" originally published in Journal for Immunotherapy of Cancer (JITC) on December 24, 2020 and has since been updated.
SITC continuously evaluates the field for practice-changing data and new FDA approvals. The SITC Lymphoma Guideline Expert Panel will guide the development of updates within this CPG. Updates appear in the SITC CPG Mobile App and as annotated text accompanying the original publication in JITC.
Highlights of Updated Content:
SITC is pleased to offer companion education resources in support of the lymphoma CPG. These activities feature faculty comprised of the guideline Expert Panel and are designed to provide a deeper understanding of the recommendations in SITC guidelines and how to apply them in various clinical scenarios. Below is a list of the available guideline education resources, including one-hour webinars that provide in-depth insights into guideline recommendations, as well as mini-modules focusing on specific topics within the content. Videos are available free and on-demand.
Immunotherapy for the Treatment of Lymphoma CPG Overview
Practical Management Pearls for Immunotherapy for the Treatment of Lymphoma
This one hour on-demand webinar features members of the guideline Expert Panel who discuss how to appraise and classify organ-specific considerations for immunotherapy agents and toxicities, identify and manage clinically significant uncommon toxicities, and determine optimal sequencing of immunotherapies in relapsed and/or refractory disease.
Case Studies in Immunotherapy for the Treatment of Lymphoma
This one hour on-demand webinar features members of the guideline Expert Panel. These faculty members discuss case studies that illustrate execution of SITC guideline recommendations, as well as discussion on difficult topics related to case management.
Dr. Joshua Brody - Icahn School of Medicine at Mount Sinai, describes the use of bispecific T cell engager therapy in a patient with NHL. Efficacy and safety of bispecifics are discussed.
Integration with Transplant
Dr. Justin Kline, University of Chicago, outlines the role of CAR T and immune checkpoint inhibitor treatments in sequence with autogolous and allogenic stem cell transplant. Considerations such as safety and efficacy are discussed.
For questions regarding SITC CPGs, please contact a member of the Scientific Publications Department at firstname.lastname@example.org.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com